Brennan is vice president and general manager of neurology and business development for Lundbeck U.S. The neurology business unit is responsible for commercializing several products, including Xenazine (tetrabenazine, Huntington disease), Sabril (vigabatrin, refractory partial complex seizures), Onfi (clobazam, Lennox-Gastaut disease) and Northera (droxidopa, neurogenic orthostatic hypotension as a result of neurological disorders and other means).
Oldani is the midwest director of State Government Affairs for Eli Lilly. The global pharmaceutical research-based company, headquartered in Indianapolis, Ind., has a heritage more than 135 years strong, with approximately 39,000 employees worldwide. Oldani represents the company in public, private and professional forums addressing policy issues involving the healthcare industry. She is responsible for monitoring the legislative, regulatory, administrative and political processes that affect government funded healthcare programs, as well as their impact upon industry.
Resatz, Ph.D., president of Vetter Development Services USA, heads Vetter’s clinical manufacturing facility in suburban Chicago, Ill. Vetter is an independent international contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany. Its Chicago facility is the company’s first U.S. site, and provides development support and aseptic manufacturing for preclinical through phase IIb injectables, primarily complex biologics.
Vemuri joined Baxter in January 2012 as vice president, head of Baxter Ventures, the corporation's $200 million venture fund. Previously, she was a general partner at Quaker Partners, where she led investments in biopharmaceutical and healthcare companies and was an integral part of the team raising capital for the funds. Vemuri's role in building and mentoring portfolio companies has facilitated successful exits through acquisitions and Initial Public Offerings.
